BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials – Video

Posted by Dr. Michael White, Published on November 2nd, 2012



BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials
BioSante Pharmaceuticals (BPAX) announced today that enrollment of subjects in the second of two pivotal Phase III safety and efficacy trials for LibiGel, a testosterone gel being developed to treat female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, has been completed. Enrollment in the first efficacy trial was completed in February. The trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement.From:TradeTheTrendViews:144 0ratingsTime:00:34More inNews Politics

Read the original here:

BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials - Video

Contact Us Now

Your Name (*)
Your Email (*)
Your Phone (*)
Select A Program
Select Your US State (*)
Select your age (30+ only)
Confirm over 30 years old (*) Yes
Confirm United States Resident? (*) Yes
(*) - Required
After completing the contact form above, press the submit button. We will send you a confirmation email. Please check your email. For security purposes, please give us a call at 1-800-469-3343 if you don't receive an email.

Related Post

Word Count: 105

Comments are closed.


site injection testosterone specialist cypionate
testosterone chart supplements cream

supplements to increase testosterone levels